Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.51 |
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 0.49 |
| ▸ | SPHK2 | Q9NRA0 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29070 | 1.00 | GPR119 (0.51) | GPR119SPHK1SPHK2POLBRAB9A | |
| SCHEMBL4138845 | 0.90 | SPHK1 (0.49) | GPR119SPHK1SPHK2 | |
| SCHEMBL25176627 | 0.86 | SPHK2 (0.72) | GPR119SPHK1SPHK2 | |
| SCHEMBL16949469 | 0.84 | SPHK2 (0.51) | SPHK1SPHK2POLBRAB9AALDH1A1 | |
| SCHEMBL29308060 | 0.84 | SPHK1 (0.48) | GPR119SPHK1SPHK2HPGD | |
| SCHEMBL25170389 | 0.84 | SPHK1 (0.48) | GPR119SPHK1SPHK2HPGD | |
| SCHEMBL8288204 | 0.83 | PRMT5 (0.48) | GPR119POLBALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL15785127 | 0.82 | GPR119 (0.62) | GPR119POLBRAB9AALDH1A1KMT2A | |
| SCHEMBL4954639 | 0.81 | HCRTR1 (0.56) | — | |
| SCHEMBL4954645 | 0.81 | HCRTR1 (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130231373-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES | NOVARTIS AG (CH) | 2013-09-05 | — | — | US | disclosed |
| EP-2609078-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES | Novartis AG (CH) | 2013-07-03 | — | — | EP | disclosed |
| WO-2012025164-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES | NOVARTIS AG (CH) | 2012-03-01 | — | — | WO | disclosed |
| US-20110060009-A1 | Hydroxamate-Based Inhibitors of Deacetylases | NOVARTIS AG | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231373-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES | HDAC1, HDAC11, HDAC3 | GPR119 339/4885SPHK1 1916/4885SPHK2 1638/4885 |
| US-20110060009-A1 | Hydroxamate-Based Inhibitors of Deacetylases | HDAC1, HDAC11, HDAC3 | GPR119 415/4885SPHK1 1729/4885SPHK2 1514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.